In 2023, Nigeria accounted for nearly 26 percent of all malaria cases worldwide, by far the highest share of any country. The Democratic Republic of the Congo had the second-highest share of malaria cases that year with 12.6 percent, followed by Uganda with 4.8 percent. Malaria is an infectious disease spread by female mosquitoes. Symptoms include fever, fatigue, vomiting, and headache and if left untreated the disease may lead to death. The region most impacted by malaria In 2023, there were a total of 263,000 cases of malaria worldwide. The region of Africa accounted for 246,000 of these cases, making it by far the region most impacted by this deadly disease. In comparison, Southeast Asia reported four thousand malaria cases in 2023, while the Americas had just 548. However, incidence rates of malaria have decreased around the world over the past couple decades. In Africa, the incidence rate of malaria decreased from 369 per 1,000 at risk in the year 2000 to 223 per 1,000 at risk in 2022. Worldwide, the incidence rate of malaria decreased from 79 to 60 per 1,000 at risk during this period. How many people die from malaria each year? Although rates of malaria have decreased around the world, hundreds of thousands of people still die from malaria each year, with the majority of these deaths in Africa. In 2023, around 597,000 people died from malaria worldwide, with 569,000 of these deaths occurring in Africa. However, death rates from malaria have decreased in Africa, with a rate of 62.5 per 100,000 at risk in the year 2015 compared to a rate of 52.4 per 100,000 at risk in 2023. In 2023, Nigeria accounted for around 31 percent of all malaria deaths, while 11 percent of such deaths were in the Democratic Republic of the Congo.

Although malaria has become more preventable across the Asia-Pacific region throughout recent years, Papua New Guinea recorded over ****** thousand cases of malaria as of 2020. In comparison, Timor-Leste had approximately ** recorded cases of malaria in 2020.

What is malaria? Malaria is a disease caused by the bite of a mosquito which is infected by the Plasmodium parasite. Malaria is typically rife in hot countries, as the parasite is able to live in these climates. After Africa and the Eastern Mediterranian, Southeast Asia was the region which had the third highest number of malaria cases worldwide in 2020. That year, Southeast Asia also suffered the third highest number of deaths due to malaria, which was significantly higher than the Western Pacific region.

Attempts to tackle the disease Many countries across the Asia Pacific region have increased attempts to tackle malaria, with members of the World Health Organization (WHO) adopting aims a resolution to have eradicated the disease by 2030. Although malaria started to decrease from 2010 in Southeast Asia, the number of cases rose once more in 2015 and 2016. Subsequently, the Southeast Asian region adopted initiatives to lower the rate of infection. As of November 2017, the region made the funding of new technologies to end malaria a priority. Interestingly, the number of malaria cases in Southeast Asia then decreased in 2017, and continued to decline steadily in the following years.

Africa is the region most affected by malaria in the world. Over ***** million cases of the disease were reported in the continent in 2022. From a country perspective, the Democratic Republic of the Congo registered the highest number of cases, some **** million, followed by Nigeria, with **** million cases. Overall, the total number of reported deaths due to the disease in Africa was around ****** as of 2022.

Global Malaria Cases Reported Share by Country (Units (Cases)), 2023 Discover more data with ReportLinker!

Africa is the region most affected by malaria in the world. The total number of reported deaths in the continent due to the disease was around 91,300 deaths in 2022, increasing slighly from 91,100 deaths thousand in the previous year. From a country perspective, the Democratic Republic of the Congo registered the highest amount of casualties, nearly 24,900 , followed by Angola, with some 12,500 deaths.

Malaria incidence (per 1000 population at risk) for African Countries

  Dataset Description

This dataset contains 'Malaria incidence (per 1000 population at risk)' data for all 54 African countries, sourced from the World Health Organization (WHO). The data is structured with years as rows and countries as columns, facilitating time-series analysis. The data is measured in: per 1000 population at risk. Missing values have been handled using linear interpolation followed by… See the full description on the dataset page: https://huggingface.co/datasets/electricsheepafrica/Malaria-Incidence-Per-1000-Population-At-Risk-for-African-Countries.

The data provide a summary of the quantities of malaria commodities procured under the USAID/DELIVER PROJECT Task Order Malaria by country and by year. The data has two sheets on historical procurements per country and stockpiles for three countries (Democratic Republic of the Congo, Kenya, and South Sudan).

Global Incidence of Malaria by Country, 2023 Discover more data with ReportLinker!

Analysis of ‘Malaria in Africa’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/lydia70/malaria-in-africa on 28 January 2022.

--- Dataset description provided by original source is as follows ---

Context

Africa, the world's second-largest continent, a continent with a wide array of vibrant cultures each with its own deep history, continent number 2 of largest population, and the continent is home to wonderful wildlife you can spot when you go on safari! Let's focus on Africa in this dataset.

Malaria is a common disease in Africa. The disease is transmitted to humans through infected mosquito bites. Although you can take preventive measures against malaria, it can be life-threatening. This dataset includes the malaria cases in African countries, the incidence at risk, and data on preventive treatments against malaria.

Content

This dataset includes data on all African countries from 2007 till 2017. Each country has a unique ISO-3 country code, and the dataset includes the latitude and longitude point of each country as well. The dataset includes the cases of malaria that have been reported in each country and each year, as well as data on preventive measures that have been taken to prevent malaria.

Acknowledgements

The data on the incidence of malaria, malaria cases reported, and preventive treatments against malaria have been retrieved from the world bank open data source.

Inspiration

Each country has a unique ISO-3 country code. You can use the ISO-3 code to create choropleth maps and in the geospatial analysis. In addition, the dataset includes latitude and longitude points for each country.

Drinking water safety and sanitation include a risk factor for malaria. Can improved drinking water facilities and preventive measures decrease the risk of malaria infection?

Check out my notebook submission, feel free to copy the kernel for your analysis: https://www.kaggle.com/lydia70/notebook-malaria-in-africa The notebook submission includes geospatial analysis with plotly.

--- Original source retains full ownership of the source dataset ---

The President’s Malaria Initiative (PMI) is a U.S. Government initiative designed to reduce malaria deaths and illnesses in target countries in sub-Saharan Africa with a long-term vision of a world without malaria. This asset contains two data files that hold budget code information for projects with the associated FY18 budget and activity descriptions. USAID has made these data publicly available since 2006 as part of the Country Malaria Operating Plans. The data are updated annually.

In 2023, Nigeria accounted for **** percent of malaria deaths worldwide. This statistic shows the distribution of malaria deaths globally in 2023.

Malaria is a common and serious disease that primarily affects developing countries and its spread is influenced by a variety of environmental and human behavioral factors; therefore, accurate prevalence prediction has been identified as a critical component of the Global Technical Strategy for Malaria from 2016 to 2030. While traditional differential equation models can perform basic forecasting, supervised machine learning algorithms provide more accurate predictions, as demonstrated by a recent study using an elastic net model (REMPS). Nevertheless, current short-term prediction systems do not achieve the required accuracy levels for routine clinical practice. To improve in this direction, stacked hybrid models have been proposed, in which the outputs of several machine learning models are aggregated by using a meta-learner predictive model. In this paper, we propose an alternative specialist hybrid approach that combines a linear predictive model that specializes in the linear component of the malaria prevalence signal and a recurrent neural network predictive model that specializes in the non-linear residuals of the linear prediction, trained with a novel asymmetric loss. Our findings show that the specialist hybrid approach outperforms the current state-of-the-art stacked models on an open-source dataset containing 22 years of malaria prevalence data from the city of Ibadan in southwest Nigeria. The specialist hybrid approach is a promising alternative to current prediction methods, as well as a tool to improve decision-making and resource allocation for malaria control in high-risk countries.

This data asset contains facility-based data on malaria stock status, commodity management, and case management. The President’s Malaria Initiative (PMI) is a U.S. Government initiative designed to reduce malaria deaths and illnesses in target countries, particularly in sub-Saharan Africa, with a long-term vision of a world without malaria. Enacted in 2005, the current strategy sets out to meet the following goals: (1) reduce malaria mortality by one-third from 2015 levels in PMI-supported countries, achieving greater than 80% reduction from PMI’s original 2000 levels; (2) reduce malaria morbidity in PMI-supported countries by 40% from 2015 levels; and (3) assist at least five PMI-supported countries to meet the WHO criteria for national or sub-national pre-elimination. The strategy is built around five focus areas to achieve these goals: (1) Achieving and sustaining scale of proven interventions; (2) adapting to changing epidemiology and incorporating new tools; (3) improving countries’ capacity to collect and use information; (4) mitigating risk against the current malaria control gains; and (5) building capacity and health systems. The data contains information about malaria case management, commodity management for the following countries: Burkina Faso, Ghana, Liberia, Malawi, Mozambique, Nigeria, Tanzania, Zambia, and Zimbabwe.

BackgroundPrimaquine is a key drug for malaria elimination. In addition to being the only drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole effective treatment of infectious P. falciparum gametocytes, and may interrupt transmission and help contain the spread of artemisinin resistance. However, primaquine can trigger haemolysis in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PDd). Poor information is available about the distribution of individuals at risk of primaquine-induced haemolysis. We present a continuous evidence-based prevalence map of G6PDd and estimates of affected populations, together with a national index of relative haemolytic risk. Methods and FindingsRepresentative community surveys of phenotypic G6PDd prevalence were identified for 1,734 spatially unique sites. These surveys formed the evidence-base for a Bayesian geostatistical model adapted to the gene's X-linked inheritance, which predicted a G6PDd allele frequency map across malaria endemic countries (MECs) and generated population-weighted estimates of affected populations. Highest median prevalence (peaking at 32.5%) was predicted across sub-Saharan Africa and the Arabian Peninsula. Although G6PDd prevalence was generally lower across central and southeast Asia, rarely exceeding 20%, the majority of G6PDd individuals (67.5% median estimate) were from Asian countries. We estimated a G6PDd allele frequency of 8.0% (interquartile range: 7.4–8.8) across MECs, and 5.3% (4.4–6.7) within malaria-eliminating countries. The reliability of the map is contingent on the underlying data informing the model; population heterogeneity can only be represented by the available surveys, and important weaknesses exist in the map across data-sparse regions. Uncertainty metrics are used to quantify some aspects of these limitations in the map. Finally, we assembled a database of G6PDd variant occurrences to inform a national-level index of relative G6PDd haemolytic risk. Asian countries, where variants were most severe, had the highest relative risks from G6PDd. ConclusionsG6PDd is widespread and spatially heterogeneous across most MECs where primaquine would be valuable for malaria control and elimination. The maps and population estimates presented here reflect potential risk of primaquine-associated harm. In the absence of non-toxic alternatives to primaquine, these results represent additional evidence to help inform safe use of this valuable, yet dangerous, component of the malaria-elimination toolkit. Please see later in the article for the Editors' Summary

Malaria Treatment Market Outlook

The global malaria treatment market size was valued at approximately USD 982 million in 2023, and it is projected to reach around USD 1,456 million by 2032, growing at a compound annual growth rate (CAGR) of 4.4% during the forecast period. The primary growth factor driving this market is the increasing prevalence of malaria in certain regions, necessitating continuous innovation and distribution of effective treatment options.

The rising incidence of malaria, particularly in tropical and subtropical regions, has been a significant growth driver for the market. Factors such as climate change, increasing population, and inadequate healthcare infrastructure in developing countries have contributed to the sustained high prevalence of malaria. Consequently, the demand for effective malaria treatments has been on the rise, pushing market growth. Furthermore, the global focus on eradicating malaria through various public health initiatives and increased funding from governments and non-profit organizations are fostering advancements in treatment methods and drug development.

Another critical growth factor is the innovation and development of new antimalarial drugs. Pharmaceutical companies and research institutions are investing heavily in discovering novel treatments that are more effective and have fewer side effects. The emergence of drug-resistant malaria strains has prompted a wave of research into new drug formulations and combinations. These advancements not only promise better outcomes for patients but also offer new market opportunities for pharmaceutical companies, thereby driving market growth further.

Moreover, the growing awareness and education about malaria prevention and treatment have positively impacted the market. Various global health organizations are actively involved in spreading awareness about the importance of early diagnosis and treatment of malaria. Campaigns and initiatives aimed at educating people in endemic regions about the symptoms of malaria and the necessity of seeking prompt medical attention have increased the uptake of malaria treatments, thus fueling market expansion.

Regionally, the Asia Pacific and Africa are the most affected by malaria, and thus, they represent the largest market for malaria treatments. Countries in these regions are heavily burdened by the disease, which has led to significant investments in healthcare infrastructure and efforts to improve access to effective treatments. Additionally, international collaborations and funding have facilitated the distribution of malaria treatments in these regions, further supporting market growth. The North American and European markets, though less impacted by malaria, contribute to market growth through research and development activities and funding for global malaria eradication programs.

In addition to malaria, there is a growing focus on addressing Neglected Tropical Disease Treatments, which encompass a range of diseases that disproportionately affect impoverished communities in tropical regions. These diseases, often overlooked in global health priorities, include conditions such as dengue, leishmaniasis, and lymphatic filariasis. Efforts to develop and distribute effective treatments for these diseases are gaining momentum, with increased funding and research initiatives aimed at improving health outcomes in affected regions. The integration of NTD treatments into broader public health strategies is essential for addressing the health disparities faced by vulnerable populations and enhancing overall disease management.

Drug Type Analysis

The malaria treatment market can be segmented by drug type into antimalarial drugs, antibiotics, and antipyretics. Antimalarial drugs constitute the largest segment in this category, driven by their essential role in directly targeting the malaria parasite. These drugs, including artemisinin-based combination therapies (ACTs) and quinine derivatives, are the cornerstone of malaria treatment protocols recommended by the World Health Organization (WHO). The ongoing development and distribution of new antimalarial formulations are crucial in combating drug-resistant strains, making this segment highly dynamic and critical for market growth.

Antibiotics serve as an adjunct treatment in malaria management, particularly in cases where bacterial infections complicate malaria. These drugs help manage secondary infections that

Additional file 9. Average annual mean temperature for Zimbabwe downloaded from Climate Change Knowledge Portal (CCKP) (Available at: https://climateknowledgeportal.worldbank.org/country/zimbabwe/climate-data-historical ).

The data provide a summary of the quantities of malaria commodities procured under the USAID/DELIVER PROJECT Task Order Malaria by country and by year. The data has two sheets on historical procurements per country and stockpiles for three countries (Democratic Republic of the Congo, Kenya, and South Sudan).

Extract from Abstract [Related Publication]

Background: maintaining the effectiveness of the currently recommended malaria vector control interventions while integrating new interventions will require monitoring key recommended indicators to identify threats to effectiveness including physiological and behavioural resistance to insecticides.

Methods: Country metadata on vector surveillance and control activities was collected using an online survey by national malaria control programmes or partner organization officials. Country and regional surveillance activities were analysed for alignment with indicators for priority vector surveillance objectives recommended by the World Health Organization. Surveillance activities were also compared for countries in the E2020 (eliminating countries) and countries with more intense transmission.

Extract from Survey:

With the support of the Bill and Melinda Gates Foundation, we are undertaking an evaluation of malaria vector surveillance in countries attempting malaria elimination in the E8, Greater Asia-Pacific Subregion and MesoAmerica. The overall objective is to establish a process to improve malaria vector surveillance, as we believe that good surveillance will maintain and improve the effectiveness of malaria vector control strategies. The process of improving vector surveillance encompasses several components. The following questionnaire which we are asking you to complete addresses the first component: to determine what surveillance activities are routinely (within the last year) carried out in the countries in which you work (if you are involved in malaria control in more than one country, please fill out a separate form for each country). This component includes a gap analysis of program capacity (including training) for vector surveillance as well as a data gap analyses to determine what vector parameters are being monitored, how they are measured and how the resulting vector information informs programmatic decisions. In the second component we will examine the capabilities of our surveillance tools (e.g., can the tools available provide the information that you require for effective decision-making or is there a technology gap). This analysis will be used to develop Target Product Profiles (TPPs) describing the requirements of future surveillance tools to improve how we monitor vectors.

We hope that this survey questionnaire will provide a high level overview of the surveillance activities in your countries and we will follow up with as many of you as possible to gather more detailed information on what you need to improve the effectiveness of malaria vector control. If you indicate that you routinely collect data on vectors, we would ask for your willingness to make this information available to allow us to access where we need to invest to understand the vectors of malaria better in order to understand where new emerging control methods might be most effective.

We appreciate your taking the time to fill out the survey. It is our hope that the analyses based on your responses will provide a strong argument for future investments to produce better training protocols as well as better methods for monitoring vectors and communicating that data to decision makers. Individual country data that is collected will be treated as confidential and will not disseminated. However, the summary data will be shared with the malaria control programs that participate in the survey as well as with the E8 Secretariat, the Asian Pacific Malaria Elimination Network, PAHO, AFRO and ALMA.

This dataset consists of 2 spreadsheets (saved in both Excel and Open Document formats):

• XLSForm_vector_surveillance_Multi-language: includes survey questions and choices in English, French and Spanish.
• Burkot_Vector surveillance survey_Aggregated dataset: summary results include type, label (questions/instructions), responses and counts.

This dataset provides estimates of malaria mortality and cumulative probability of death from malaria for 105 countries with local malaria transmission.

The Africa Malaria Diagnostics Market size was valued at USD 426.91 million in 2023 and is projected to reach USD 510.94 million by 2032, exhibiting a CAGR of 2.60 % during the forecasts period.The Africa malaria diagnostics market plays a critical role in addressing the continent's persistent challenge of malaria, a major public health concern. Malaria continues to be a leading cause of illness and death in numerous African nations, disproportionately affecting vulnerable groups such as young children and pregnant women. Prompt and accurate diagnosis is essential for timely treatment and management of the disease, primarily caused by Plasmodium parasites transmitted through infected mosquitoes. The market encompasses various diagnostic methods, including rapid diagnostic tests (RDTs), microscopy, and molecular diagnostics such as polymerase chain reaction (PCR) tests. Rapid diagnostic tests (RDTs) have gained prominence due to their simplicity, speed, and reliability, making them suitable for settings with limited access to laboratory facilities. These tests detect specific malaria antigens in a patient's blood, delivering rapid results that enable healthcare providers to initiate appropriate treatment promptly. Microscopy remains integral in many healthcare facilities despite being more labour-intensive and requiring skilled technicians; it is valued for its ability to identify malaria parasites and determine the species, which is crucial for treatment decisions. The market encounters challenges such as the need for sustained investment in healthcare infrastructure, efficient supply chain management to ensure widespread availability of diagnostics in remote areas, and ensuring affordability for marginalized communities. Recent developments include: In October 2023, South Korean in-vitro diagnostics maker Noul Co signed a sales deal in Angola, valued at around 2 billion won (USD 1.4 million), which involves the company's malaria diagnostic platform. Noul Co. also has a contract with a medical device wholesaler in Angola, a country close to Nigeria, comprising the world's highest number of malaria cases. The contract includes the supply of the automated diagnostic platform miLab and malaria diagnostic cartridges through 2028 , In November 2022, Sherlock Biosciences announced a licensing agreement with Shanghai-based Tolo Biotech. This agreement grants both companies co-exclusive rights to Cas12 and Cas13 CRISPR diagnostic methods in markets outside of Nigeria and Greater China. As the only two companies with rights to these method patents in the diagnostics market, this agreement strengthens the collaboration between Sherlock and Tolo, providing them with the most comprehensive portfolio of diagnostic CRISPR patents . Key drivers for this market are: Awareness programs and educational campaigns have increased public awareness about the importance of early diagnosis and treatment, thereby boosting the demand for diagnostic tests.. Potential restraints include: Limited healthcare infrastructure, particularly in rural and remote areas, hampers the distribution and accessibility of diagnostic tools.. Notable trends are: There is a shift towards POCT devices due to their ease of use, rapid results, and suitability for decentralized settings..